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i.org/1paravalvular regurgitation (PVR). The aim of this study was to assess the impact of iter-
ations of balloon-expandable valves (SAPIEN, SAPIEN XT, and SAPIEN 3) and degree of
aortic valve calciﬁcation (AVC) on the severity of PVR after transcatheter aortic valve
implantation (TAVI). Comprehensive echocardiographic examinations and multidetector
computed tomography (MDCT) were performed in 272 patients (127 men, 81 – 7 years old,
logistic EuroScore of 21 – 13%) who underwent TAVI with 23- and 26-mm balloon-
expandable valves. The degree of AVC was assessed with MDCT. PVR grade was
assessed with echocardiography. The cover index was calculated as (prosthesis area L
MDCT annulus area)/prosthesis area. SAPIEN, SAPIEN XT, and SAPIEN 3 prostheses
were implanted in 103 patients (38%), 105 patients (38.5%), and 64 patients (23.5%),
respectively. Signiﬁcant PVR (‡moderate) occurred in 14%, 10%, and 0% of patients
receiving the SAPIEN, SAPIEN XT, and SAPIEN 3, respectively (p [ 0.010). Across the
groups, the aortic annulus size, degree of calciﬁcation, and cover index were comparable.
Larger burden of AVC was independently associated with signiﬁcant PVR (odds ratio 3.48,
p [ 0.006) after adjusting for age, body surface area, gender, aortic annulus area,
cover index, and prosthesis iteration. SAPIEN 3 was associated with lower frequency of
signiﬁcant PVR (odds ratio 0.31, p [ 0.002). In conclusion, the incidence of signiﬁcant
PVR signiﬁcantly decreased over time with improvement in valve design. SAPIEN 3
was associated with less signiﬁcant PVR after TAVI independently of the AVC
burden.  2016 Elsevier Inc. All rights reserved. (Am J Cardiol 2016;118:567e571)The SAPIEN 3 THV (S3-THV; Edwards Lifesciences Inc,
Irvine, California) is the newest generation of balloon-
expandable bioprosthetic aortic valve, which received US
Food and Drug Administration approval in June 2015 for
treatment of patients at high risk with severe, symptomatic
aortic stenosis (AS) (Figure 1). The SAPIEN 3 valve has been
associated with lower incidence of signiﬁcant paravalvular
regurgitation (PVR) in a multicenter registry recently.1,2 The
new features of this device, a new cobalt-chromium frame
with large cell design containing the valve and an outer
polyethylene terephthalate cuff enhance the sealing of the
aortic annulus and the gaps between the prosthetic frame and
the native valve caused by the presence of extensive, asym-
metric bulky calciﬁc deposits.3 The effect of valve iterationsof aCardiology and cCardiothoracic surgery, Leiden
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0.1016/j.amjcard.2016.05.053and degree of aortic valve calciﬁcation (AVC) on the severity
of PVR after transcatheter aortic valve implantation (TAVI)
has not been evaluated. The aim of this study was to investi-
gate the impact of iteration of these balloon-expandable
valves (SAPIEN, SAPIEN XT, and SAPIEN 3) and degree
of AVC on the PVR severity in patients with severe AS.
Methods
From November 2007 till June 2015, all patients with
symptomatic severe AS treated with balloon-expandable
transcatheter aortic bioprostheses (SAPIEN, SAPIEN XT,
and SAPIEN 3) at the Leiden University Medical Center
were included. Patients receiving self-expandable valves,
29-mm balloon-expandable prosthesis or undergoing valve-
in-valve procedures were excluded from this study. Patients
deemed too high risk for surgical options with high logistic
EuroSCORE and contraindications for surgery (porcelain
aorta, frailty, severe chronic obstructive airway disease, and
previous coronary artery bypass grafting) were referred for
TAVI. Demographics, clinical, echocardiographic, multi-
detector row computed tomographic (MDCT) data and
procedure data were prospectively collected in our center
database (EPD Vision, version 8.3.3.6; Leiden, the
Netherlands) for retrospective analysis.
All the TAVI candidates underwent detailed clinical and
imaging workup. Either a 64-detector or 320-detector rowwww.ajconline.org
Figure 1. Edward SAPIEN 3 transcatheter heart valve. The new SAPIEN 3 valve is characterized for a low frame height, including an inner and an outer sealing
skirt to reduce the PVR. Courtesy of Edwards Lifesciences (https://edwardslifesciences.box.com/s/1yxhofw4adrqkeimz2vyjc99jmuy0jmz).
Table 1
Baseline and echocardiographic characteristics before transcatheter aortic valve implantation
Variable Sapien
(n¼103)
Sapien XT
(n¼105)
Sapien 3
(n¼64)
p-value
Age, (years) 81  7.5 81  6.2 81  5.1 0.756
Male 54 (52%) 49 (47%) 29 (45%) 0.595
Body surface area (m2) 1.82  0.18 1.82  0.18 1.81  0.20 0.867
Sinus rhythm/atrial ﬁbrillation/pacemaker 71 (69%) / 19 (18%) / 13 (13%) 78(74%) / 16 (15%) / 11 (11%) 42 (66%) / 16 (25%) / 6 (9%) 0.572
Hypertension 81 (79%) 76 (72%) 49 (77%) 0.566
Diabetes mellitus 31 (30%) 26 (25%) 19 (30%) 0.650
Hypercholesterolemia 81 (79%) 77 (73%) 43 (67%) 0.258
Previous myocardial infarction 29 (28%) 19 (18%) 9 (14%) 0.061
Previous coronary bypass grafting 45 (44%) 23 (22%) 23 (36%) 0.018
Preoperative creatinine (mmol/L) 108  60 93  34 100  54 0.116
Estimated glomerular ﬁltration
rate (ml/min/1.73m2)
63  23 69  23 68  25 0.138
Haemoglobin, (mmol/L) 7.6  1.0 7.7  1.1 8.0  1.4 0.057
Logistic EuroSCORE (%) 24.8  13.3 21.0  13.6 15.5  7.9 <0.001
Echocardiography
Left ventricular ejection fraction, % 52.2  14.3 55.6  14.8 58.4  15.6 0.029
Aortic valve area, (cm2/m2) 0.7  0.2 0.7  0.2 0.7  0.2 0.994
Mean aortic gradient, (mmHg) 39.5  16.0 43.9  18.7 41.8  15.2 0.164
Maximal aortic gradient, (mmHg) 64.1  24.1 71.9  28.6 67.4  23.8 0.095
Medications
b-blockers 65 (63%) 69 (66%) 42 (66%) 0.911
Angiotensin converting enzyme
inhibitors / Angiotensin
receptor blockers
63 (61%) 59 (56%) 27 (42%) 0.053
Diuretics 75 (73%) 65 (62%) 34 (53%) 0.031
Calcium channel blocker 33 (32%) 29 (28%) 12 (19%) 0.171
Statins 78 (76%) 60 (57%) 35 (55%) 0.005
Aspirin 55 (53%) 59 (56%) 31 (48%) 0.619
Oral anticoagulants 38 (37%) 29 (28%) 19 (30%) 0.331
568 The American Journal of Cardiology (www.ajconline.org)computed tomography scanner (Aquilion 64 and Auilion
ONE, respectively; Toshiba Medical Systems, Otawara,
Japan) was used to assess the aortic annular size, the
dimension of all the segments of the aorta, the degree and
location of the AVC, and the anatomy of the peripheral
arteries. The MDCT data acquisition protocol for the
Aquilion 64 and Aquilion ONE has been previouslydescribed.4 Patients with heart rate more than 65 beats/min
received either an oral beta blocker (50 to 100 mg meto-
prolol), unless contraindicated. Scanning was performed
during midinspiratory breath-holding. The arrival of bolus
media was detected using a real-time tracking technique
with a threshold of þ180 Hounsﬁeld units. All the MDCT
data were recorded and stored for postprocessing. Aortic
Table 2
Procedural and imaging characteristics of the population
Variable Sapien
(n¼103)
Sapien XT
(n¼105)
Sapien 3
(n¼64)
p-value
Transapical 62 (60%) 71 (68%) 15 (23%) <0.001
Sapien Prosthesis size 0.022
23 mm 23 (22%) 35 (33%) 27 (42%)
26 mm 80 (78%) 70 (67%) 37 (58%)
Intraprocedural grade of paravalvular regurgitation moderate 14 (14%) 10 (10%) 0 0.010
Aortic annulus area derived from MDCT, (mm2) 443  87 444  68 427  65 0.293
Cover index, (%) 11.97  15.45 9.52  11.23 11.39  8.48 0.344
Agatston calcium score of the aortic valve
Mean 3061  1468 31941981 31291449 0.850
Median 2771 [1940-4070] 2723 [1806-4089] 2860 [2129-4124] 0.859
MDCT ¼ multidetector row computed tomography.
Figure 2. PVR evaluated by transeosophageal echocardiography immedi-
ately after TAVI. Note the signiﬁcant reduction in moderate and severe
PVR frequency after TAVI (13.7% in the SAPIEN group, 9.6% in the
SAPIEN XT, and 0% in the SAPIEN 3 group; p ¼ 0.01).
Valvular Heart Disease/PVR Across SAPIEN Iterations 569annulus dimensions (perimeter, maximum diameter, mini-
mum diameters, and aortic valve area) were measured
according to the standard protocol.5 For quantitative
assessment of AVC, Agatston score of the aortic valve was
assessed (including a volume from the aortic annulus until
the level of the coronary ostia including left ventricular
outﬂow tract [LVOT]).6 The cover index was calculated as
(prosthesis areaMDCT annulus area)/prosthesis area, as
previously described.7 Comprehensive transthoracic echo-
cardiography was performed before TAVI with a commer-
cially available ultrasonographic system (Vingmed Vivid;
General Electric Vingmed, Horten, Norway). Valve
morphology, AS severity, and left ventricular (LV) function
were measured according to the European Association of
Cardiovascular Imaging/American Society of Echocardiog-
raphy standards.8 LV ejection fraction was calculated by the
Simpson’s biplane method. For quantiﬁcation of aortic
valve regurgitation, the jet deceleration slope (pressure
halftime), jet width or jet area, vena contracta, and the
diastolic ﬂow reversal in the descending aorta were
considered in an integrative approach.9
TAVI was performed through transfemoral or transapical
approach, based on the feasibility of the iliofemoral anatomy
and suitable access sites. All procedures were performed in a
fully equipped hybrid cardiac catheterization laboratory.
Surgical cutdown or suture-mediated closure device
(Perclose ProGlide; Abbott laboratories, Abbott Park, Illi-
nois) were used to close the vascular access site at the
femoral arteries. All procedures were performed under
general anesthesia. Transesophageal echocardiography was
used to support TAVI procedures, and ﬂuoroscopy was used
to guide the deployment of the valves and prosthesis posi-
tioning. Both predilatation of the native valve and prosthetic
valve implantation were performed during rapid right
ventricular pacing (160 to 200 beats/min) as previously
described.10 Prosthesis position, function, and coronary
ostia patency were assessed with transesophageal echocar-
diography and ﬂuoroscopy. After implantation of the TAVI
bioprosthesis, the presence and severity of aortic regurgi-
tation (both transvalvular and paravalvular) was assessed
with transesophageal echocardiography and classiﬁed
according to the Valve Academic Research Consortium
(VARC)-2 recommendations.11 The severity of the PVR
was classiﬁed as none, trace, mild, moderate, and severe.The circumferential extend of the PVR was assessed in the
parasternal short-axis views with color Doppler.12,13 The
localization and severity of the PVR was judged in the
midesophageal and transgastric views. Moderate or higher
grade of PVR was treated with further postdilatation or
second valve implantation, with agreement among the Heart
Team members present during the procedure.
Continuous variables are expressed as mean  SD or as
median (interquartile range) if not normally distributed.
Categorical variables are presented as frequency and
percentage. For comparison of continuous variables, the
Student t test, 1-way analysis of variance (with Bonferroni
post hoc analysis), or the ManneWhitney U test were used,
as appropriate. For comparison of categorical variables, the
chi-square test was used. Univariate and multivariate binary
logistic regression analyses were performed. Odds ratios and
95% CIs were reported. Statistical analysis was performed
using SPSS software, version 20 (IBM Corp, Armonk, New
York). A p value <0.05 deﬁned statistical signiﬁcance.
Results
Baseline characteristics, echocardiographic features, and
medication use of 272 patients (mean age 81  7 years, 52%
Table 3
Univariate and multivariate associates of PVR after TAVI
Variable Univariate Multivariate
Odds ratio
(95% conﬁdence
interval)
p-value Odds ratio
(95% conﬁdence
interval)
p-value
Aortic annulus area derived from MDCT, (mm2) 1.006 (1.000-1.011) 0.045 0.997 (0.988-1.006) 0.480
Cover index, (%) 0.016 (0.001-0.387) 0.011 0.012 (0.000-2.038) 0.083
Log transformed Agatston calcium score 2.997 (1.318-6.817) 0.009 3.478 (1.424-8.498) 0.006
SAPIEN 3 valve 0.381 (0.194-0.749) 0.005 0.306 (0.146-0.642) 0.002
MDCT ¼ multidetector row computed tomography.
570 The American Journal of Cardiology (www.ajconline.org)women) are presented in Table 1. The SAPIEN valve was
implanted in 103 patients (38%), 105 patients (39%)
received a SAPIEN XT, and 64 patients (24%) received a
SAPIEN 3. The SAPIEN 3 group had a lower percentage of
patients with previous coronary artery bypass grafting,
lower logistic EuroScore, more preserved LV ejection
fraction, and lower number of patients using diuretics or
statins than the other groups (Table 1).
The MDCT and procedural characteristics for each group
are illustrated in Table 2. There were no differences in the
aortic annulus area, percentage of cover index, and both
mean and median Agatston calcium score of the aortic valve
between the 3 groups. However, the transapical access was
more frequently used in the SAPIEN and SAPIEN XT
groups than in the SAPIEN 3 group. Furthermore, the
23-mm valve was more frequently used in the SAPIEN
3 group than their counterparts (Table 2).
In terms of procedural results, a signiﬁcant difference in
PVR grade was noted across groups, with a signiﬁcant
reduction in the number of patients with  moderate PVR
(14% in the SAPIEN group, 10% in the SAPIEN XT, and
0% in the SAPIEN 3 group; p ¼ 0.01; Table 2 and
Figure 2). To investigate the impact of TAVI valve iteration
on the risk of  moderate post-TAVI PVR, a multivariate
regression analysis was performed. After correcting for
aortic annulus dimensions and cover index, AVC burden
and TAVI bioprosthesis were independently associated with
 moderate PVR, whereas increasing amount of AVC was
associated with higher risk of signiﬁcant PVR, the iteration
SAPIEN 3 was associated with lower risk suggesting that
the new design features of this valve may counteract the
effects of the AVC burden (Table 3).
Discussion
The principal ﬁnding of this study is that the incidence of
signiﬁcant PVR decreased over time with the improvement
of the bioprosthesis design. The SAPIEN 3 valve was
independently associated with lower frequency of signiﬁ-
cant PVR independently of degree of AVC.
The amount and location (symmetric vs asymmetric) of
AVC are important correlates of PVR after TAVI.4,14 It has
been hypothesized that AVC plays a role in anchoring and
achieving better positioning of balloon-expandable valves.
However, excessive or asymmetric distribution of calciﬁ-
cation may lead to signiﬁcant PVR.15 The present study
demonstrated that excessive calciﬁcation of the native aorticvalve was independently associated with signiﬁcant PVR
after TAVI. This was also demonstrated by Seiffert et al16 in
a recent study including 537 patients treated with different
models of TAVI bioprostheses (SAPIEN XT, JenaValve,
Symetis, CoreValve, and Engager). Larger AVC load,
particularly at the level of the LVOT inferior to the annulus
(coefﬁcient 0.146, 95% CI 0.038 to 0.253, p ¼ 0.008), and
type of bioprosthesis (CoreValve; coefﬁcient 0.368, 95% CI
0.233 to 0.503, p <0.001) were independently associated
with PVR after TAVI. Interestingly, other types of
bioprosthesis were associated with lower frequency of sig-
niﬁcant PVR after TAVI. However, increasing AVC load
was associated with increased risk of PVR in all types of
prosthesis if the LVOT calciﬁcation exceeded 10 mm3. It
may be difﬁcult to correct the incidence of PVR for the
design characteristics of these different prostheses.
The SAPIEN 3 improves the annular sealing by incor-
porating an external cuff that ﬁlls up irregularities in adja-
cent aortic annulus and LVOT boundaries.17 The sealing
abilities of the annular cuff can minimize oversizing and
maintain valve patency without any negative impact on the
residual gradient or valve area. In addition, these features
may counterbalance the effect of AVC reducing the risk of
PVR. Results from a few recent studies have shown
promising results regarding the performance of this valve
with much lower incidence of signiﬁcant PVR. Jochheim
et al18 showed that the frequency of >mild PVR at
discharge with the SAPIEN 3 valve was lower than that of
the SAPIEN XT valve (2.0% vs8.8%, p <0.001) and that
use of the SAPIEN 3 valve was the only independent pre-
dictor of PVR. These results have been observed in other
contemporary studies.19,20 However, the association
between the grade of PVR and the degree of AVC across the
several iterations of the same valve prosthesis has not been
investigated so far. In the present study, we demonstrated
that the grade of signiﬁcant PVR is independently associated
with the degree of AVC according to Agatston calcium
scoring (log-transformed Agatston score, odds ratio 3.478,
95% CI 1.424 to 8.498, p ¼ 0.006). However, despite
having comparable amount of AVC burden, the frequency
of >mild PVR across the 3 groups of SAPIEN valve
decreased signiﬁcantly. These results suggest that the design
features of this device may counterbalance the effects of
AVC on the valve expansion.
The main limitation of our study is a single-center,
nonrandomized study. This is a retrospective comparison
of 3 different generations of balloon-expandable
Valvular Heart Disease/PVR Across SAPIEN Iterations 571bioprosthetic valves. The effect of learning curve and
changing practices in terms of reballooning of the prosthesis
or valve-in-valve implantation was not taken into consid-
eration. In addition, the results of the present study may not
be generalizable to other types of transcatheter valves. A
larger population is needed to conﬁrm the clinical end points
of severity of PVR after TAVI.
In conclusion, the third generation of balloon-expandable
SAPIEN 3 demonstrated lower incidence of signiﬁcant PVR
than the preceding SAPIEN and SAPIEN XT. Relevant
PVR after TAVI remains independently associated with
degree of AVC.Disclosures
The authors have no conﬂicts of interest to disclose.
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